Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
416.50
+12.00 (2.97%)
At close: Dec 5, 2025
193.31%
Market Cap 34.45B
Revenue (ttm) n/a
Net Income (ttm) -1.02B
Shares Out 82.73M
EPS (ttm) -12.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,171,253
Average Volume 2,094,149
Open 404.50
Previous Close 404.50
Day's Range 398.50 - 418.00
52-Week Range 91.50 - 502.00
Beta 0.02
RSI 67.36
Earnings Date Nov 13, 2025

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.